PTIX
Protagenic Therapeutics, Inc.
Price Chart
Latest Quote
$0.41
+0.00 (+0.00%)
Current Price
| Previous Close | $0.41 |
| Open | $0.41 |
| Day High | $0.41 |
| Day Low | $0.41 |
| Volume | 1,891 |
Stock Information
| Shares Outstanding | 1.81M |
| Total Debt | $4.00M |
| Cash Equivalents | $2.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $742K |
| EPS (TTM) | $-13.13 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.52M |
| Book/sh | $-1.24 |
| Cash/sh | $1.22 |
| Employees | 1 |
Financial Ratios
Returns & Margins
Ownership
| Insider Ownership | 3.84% |
| Institutional Ownership | 4.64% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.71 |
| P/B | -0.33 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.52 |
| SMA50 | $0.61 |
| SMA200 | $1.41 |
| RSI | 38.59 |
| ATR | 0.0709 |
| Short Float | 3.30% |
| Short Ratio | 0.56 |
| Rel Volume | 0.03 |
Performance History
| Week | -39.71% |
| Month | -36.92% |
| Quarter | -33.87% |
| 6 Months | -73.03% |
| YTD | -44.59% |
| Year | -88.35% |
| 3 Years | -98.46% |
| 5 Years | -99.75% |
| 10 Years | -99.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.41 | 200 |
| 2026-06-17 | $0.41 | 2,300 |
| 2026-06-16 | $0.41 | 13,100 |
| 2026-06-15 | $0.40 | 3,000 |
| 2026-06-12 | $0.50 | 58,500 |
| 2026-06-11 | $0.68 | 500 |
| 2026-06-10 | $0.54 | 5,100 |
| 2026-06-09 | $0.53 | 2,400 |
| 2026-06-08 | $0.53 | 500 |
| 2026-06-05 | $0.50 | 500 |
| 2026-06-04 | $0.50 | 6,900 |
| 2026-06-03 | $0.53 | 600 |
| 2026-06-02 | $0.50 | 4,200 |
| 2026-06-01 | $0.50 | 4,700 |
| 2026-05-29 | $0.54 | 0 |
| 2026-05-28 | $0.54 | 2,000 |
| 2026-05-27 | $0.52 | 3,200 |
| 2026-05-26 | $0.55 | 6,400 |
| 2026-05-22 | $0.62 | 0 |
| 2026-05-21 | $0.62 | 200 |
| 2026-05-20 | $0.65 | 4,100 |
| 2026-05-19 | $0.65 | 0 |
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
đ° Latest News
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires âĸ 2025-08-21T20:04:57ZTop Midday Gainers
MT Newswires âĸ 2025-08-21T17:54:29ZSector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires âĸ 2025-08-21T17:39:38ZBC-Most Active Stocks
Associated Press Finance âĸ 2025-08-21T14:30:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $107,682 | $137,456 | $496,912 |
| Total Expenses | $5,700,950 | $4,526,974 | $3,557,788 | $4,140,413 |
| Other Income Expense | $132,141 | $-630,317 | $-46,051 | $81,184 |
| Other Non Operating Income Expenses | $80,409 | - | - | - |
| Net Non Operating Interest Income Expense | $43,465 | $156,794 | $48,334 | $-463,705 |
| Interest Expense Non Operating | $0 | $107,682 | $137,456 | $496,912 |
| Operating Expense | $5,700,950 | $4,526,974 | $3,557,788 | $4,140,413 |
| General And Administrative Expense | $1,758,609 | $1,207,107 | $1,968,549 | $3,003,623 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Net Interest Income | $43,465 | $156,794 | $48,334 | $-463,705 |
| Interest Income | $43,465 | $264,476 | $185,790 | $33,207 |
| Normalized Income | $-5,577,076 | $-4,370,180 | $-3,509,454 | $-4,604,118 |
| Net Income From Continuing And Discontinued Operation | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Total Operating Income As Reported | $-5,700,950 | $-4,526,974 | $-3,557,788 | $-4,140,413 |
| Net Income Common Stockholders | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Net Income | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Net Income Including Noncontrolling Interests | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Net Income Continuous Operations | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Pretax Income | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Interest Income Non Operating | $43,465 | $264,476 | $185,790 | $33,207 |
| Operating Income | $-5,700,950 | $-4,526,974 | $-3,557,788 | $-4,140,413 |
| Per Share | ||||
| Diluted EPS | $-15.82 | $-16.10 | $-11.48 | $-17.36 |
| Basic EPS | $-15.82 | $-16.10 | $-11.48 | $-17.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,526,790 | $-4,234,280 | $-3,371,968 | $-4,107,206 |
| Total Unusual Items | $51,732 | $-630,317 | $-46,051 | $81,184 |
| Total Unusual Items Excluding Goodwill | $51,732 | $-630,317 | $-46,051 | $81,184 |
| Reconciled Depreciation | $50,286 | $28,218 | $30 | $0 |
| EBITDA (Bullshit earnings) | $-5,475,058 | $-4,864,597 | $-3,418,019 | $-4,026,022 |
| EBIT | $-5,525,344 | $-4,892,815 | $-3,418,049 | $-4,026,022 |
| Diluted Average Shares | $349,996 | $310,327 | $308,419 | $263,228 |
| Basic Average Shares | $349,996 | $310,327 | $308,419 | $263,228 |
| Diluted NI Availto Com Stockholders | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $51,732 | $-630,317 | $-46,051 | $81,184 |
| Research And Development | $3,942,341 | $3,319,867 | $1,589,239 | $1,136,790 |
| Selling General And Administration | $1,758,609 | $1,207,107 | $1,968,549 | $3,003,623 |
| Other Gand A | $1,758,609 | $1,207,107 | $1,968,549 | $3,003,623 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,013,154 | $3,668,117 | $6,917,558 | $9,941,955 |
| Total Assets | $1,955,913 | $4,323,369 | $8,037,420 | $11,059,923 |
| Total Non Current Assets | $73,046 | $123,332 | $1,775 | $0 |
| Current Assets | $1,882,867 | $4,200,037 | $8,035,645 | $11,059,923 |
| Prepaid Assets | $44,398 | $144,025 | $56,939 | $688,667 |
| Cash Cash Equivalents And Short Term Investments | $1,838,469 | $4,056,012 | $7,978,706 | $10,371,256 |
| Cash And Cash Equivalents | $1,838,469 | $1,287,893 | $215,189 | $541,171 |
| Cash Financial | $1,838,469 | $1,287,893 | $215,189 | $541,171 |
| Debt | ||||
| Net Debt | - | - | $129,041 | - |
| Total Debt | - | - | $344,230 | $318,433 |
| Current Debt And Capital Lease Obligation | - | - | $344,230 | - |
| Current Debt | - | - | $344,230 | - |
| Other Current Borrowings | - | - | $344,230 | - |
| Long Term Debt And Capital Lease Obligation | - | - | - | $318,433 |
| Long Term Debt | - | - | - | $318,433 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $942,759 | $655,252 | $1,119,862 | $1,117,968 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $318,433 |
| Current Liabilities | $942,759 | $655,252 | $1,119,862 | $799,535 |
| Payables And Accrued Expenses | $942,759 | $655,252 | $775,632 | $799,535 |
| Payables | $102,962 | $113,802 | $155,486 | $278,957 |
| Accounts Payable | $102,962 | $113,802 | $155,486 | $278,957 |
| Other Current Liabilities | - | - | - | $10 |
| Equity | ||||
| Common Stock Equity | $1,013,154 | $3,668,117 | $6,917,558 | $9,941,955 |
| Total Equity Gross Minority Interest | $1,013,154 | $3,668,117 | $6,917,558 | $9,941,955 |
| Stockholders Equity | $1,013,154 | $3,668,117 | $6,917,558 | $9,941,955 |
| Gains Losses Not Affecting Retained Earnings | $-129,850 | $-113,546 | $-676,907 | $-248,349 |
| Other Equity Adjustments | $-129,850 | $-113,546 | $-676,907 | $-248,349 |
| Retained Earnings | $-36,303,216 | $-30,777,872 | $-25,777,375 | $-22,221,870 |
| Other | ||||
| Ordinary Shares Number | $517,245 | $316,795 | $308,665 | $307,314 |
| Share Issued | $517,245 | $316,795 | $308,665 | $307,314 |
| Tangible Book Value | $1,013,154 | $3,668,117 | $6,917,558 | $9,941,955 |
| Invested Capital | $1,013,154 | $3,668,117 | $7,261,788 | $10,260,388 |
| Working Capital | $940,108 | $3,544,785 | $6,915,783 | $10,260,388 |
| Total Capitalization | $1,013,154 | $3,668,117 | $6,917,558 | $10,260,388 |
| Additional Paid In Capital | $37,445,495 | $34,559,091 | $33,371,406 | $32,411,742 |
| Capital Stock | $725 | $444 | $434 | $432 |
| Common Stock | $725 | $444 | $434 | $432 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $839,797 | $541,450 | $620,146 | $520,578 |
| Net PPE | $73,046 | $123,332 | $1,775 | $0 |
| Other Short Term Investments | $0 | $2,768,119 | $7,763,517 | $9,830,085 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,216,517 | $-3,853,551 | $-1,995,619 | $-2,798,614 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,216,517 | $-3,703,776 | $-1,993,814 | $-2,798,614 |
| Cash Flow From Continuing Operating Activities | $-4,216,517 | $-3,703,776 | $-1,993,814 | $-2,798,614 |
| Operating Gains Losses | $-51,732 | $630,317 | $46,051 | $-81,184 |
| Investing Activities | ||||
| Investing Cash Flow | $2,802,880 | $4,775,482 | $1,596,974 | $-9,909,601 |
| Cash Flow From Continuing Investing Activities | $2,802,880 | $4,775,482 | $1,596,974 | $-9,909,601 |
| Capital Expenditure | - | $-149,775 | $-1,805 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,963,546 | $0 | $0 | $11,708,039 |
| Financing Cash Flow | $1,963,546 | $0 | $0 | $12,577,664 |
| Cash Flow From Continuing Financing Activities | $1,963,546 | $0 | $0 | $12,577,664 |
| Net Common Stock Issuance | $1,963,546 | $0 | $0 | $11,708,039 |
| Common Stock Issuance | $1,963,546 | $0 | $0 | $11,708,039 |
| Net Other Financing Charges | - | - | - | $11,708,039 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $1,838,469 | $1,287,893 | $215,189 | $541,171 |
| Beginning Cash Position | $1,287,893 | $215,189 | $541,171 | $671,091 |
| Effect Of Exchange Rate Changes | $667 | $998 | $70,858 | $631 |
| Changes In Cash | $549,909 | $1,071,706 | $-396,840 | $-130,551 |
| Net Investment Purchase And Sale | $2,802,880 | $4,925,257 | $1,598,779 | $-9,909,601 |
| Sale Of Investment | $3,100,000 | $7,689,507 | $1,632,901 | $485,946 |
| Purchase Of Investment | $-297,120 | $-2,764,250 | $-34,122 | $-10,395,547 |
| Net PPE Purchase And Sale | $0 | $-149,775 | $-1,805 | $0 |
| Purchase Of PPE | $0 | $-149,775 | $-1,805 | $0 |
| Change In Working Capital | $467,543 | $-114,412 | $540,132 | $-140,389 |
| Change In Payables And Accrued Expense | $367,916 | $-27,326 | $-91,596 | $340,121 |
| Change In Prepaid Assets | $99,627 | $-87,086 | $631,728 | $-480,510 |
| Other Non Cash Items | $-80,409 | $85,770 | $110,797 | $427,137 |
| Stock Based Compensation | $923,139 | $666,828 | $864,681 | $1,518,756 |
| Depreciation Amortization Depletion | $50,286 | $28,218 | $30 | $0 |
| Depreciation And Amortization | $50,286 | $28,218 | $30 | $0 |
| Depreciation | $50,286 | $28,218 | $30 | $0 |
| Gain Loss On Investment Securities | $-51,732 | $630,317 | $46,051 | $-81,184 |
| Net Income From Continuing Operations | $-5,525,344 | $-5,000,497 | $-3,555,505 | $-4,522,934 |
| Repayment Of Debt | - | - | $0 | $-100,000 |
| Issuance Of Debt | - | - | $0 | $100,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $869,625 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | $0 | $100,000 |
| Short Term Debt Issuance | - | - | $0 | $100,000 |
| Net Long Term Debt Issuance | - | - | $0 | $-100,000 |
| Long Term Debt Payments | - | - | $0 | $-100,000 |
| Long Term Debt Issuance | - | - | $0 | $0 |
Fetched: 2026-02-02